Curriculum Vitae

Name: Paola Perrotta

Mobile Phone: +39 3425261371

E-mail: paola.perrotta2@gmail.com

EDUCATION

2012	Master of science in pharmacy School of Pharmacy, University of Siena – Siena (Italy)
2013	Advanced master degree in oncological pharmacy and pharmacology University of Milano – Milan (Italy)
2021	PhD University of Antwerp (Belgium) and University of Leiden (The Netherlands) European joint doctorate program "MoGlyNet" Marie Skłodowska-Curie ITN actions, HORIZON2020 framework

ACADEMIC REFERENCES

(Present and past references – contact information available upon request)

Prof. Wim Martinet (University of Antwerp)
Prof. Paul Quax (University of Leiden)
Prof. William Charles Sessa (Yale University)
Prof. Marina Ziche (University of Siena)
Prof. Sandra Donnini (University of Siena)
Prof. Alberto Corsini (University of Milano)

PROFESSIONAL EXPERIENCE

06/2010 – 01/2010	Pharmacy internship training
12/2011 – 07/2012	Experimental thesis (Master) Department of Life Science - University of Siena, Italy Supervisors: Prof. Marina Ziche and Sandra Donnini Thesis title: Modulation of inflammatory angiogenesis by bradykinin selective antagonists
08/2012 – 05/2014	Postgraduate Fellow Department of Life Sciences - University of Siena, Italy Supervisor: Prof. Marina Ziche Projects: - Angiogenesis in chronic inflammation - Clinical and ethical aspects in Biosimilars use for cancer therapy - Inflammation in endothelial dysfunction - Contribution of FGF-2 /FGFR1 in metastatic melanoma
06/2014 – 1/2016	Postgraduate Fellow Pharmacology Laboratory, Yale University, USA Supervisor: Prof. William Sessa
2/2016 – 3/2021	PhD student Laboratory of Physiopharmacology (University of Antwerp, Belgium) & Einthoven Laboratory for Experimental Vascular Medicine (Leiden University Medical Center, The Netherlands) Supervisors: Prof. Wim Martinet (University of Antwerp) Prof.Paul Quax and Dr Margreet R de Vries (Leiden University Medical Center)
Starting March 2022	Postdoctoral researcher Yale Cardiovascular Research Center – Yale University (USA)

FUNDED RESEARCH

2013	Agency: Italian Society of Pharmacology, Italy *"Fellowship for Young Scientist to attend a research period abroad "*
2019	Doctoral Project (DOCPRO) - University of Antwerp Research Fund

PUBLICATIONS

1. **Perrotta, P.**, de Vries, M. R., Peeters, B., Guns, P. J., De Meyer, G. R. Y., Quax, P. H. A., and Martinet, W. (2021) PFKFB3 gene deletion in endothelial cells inhibits intraplaque angiogenesis and lesion formation in a murine model of venous bypass grafting. *Angiogenesis*
2. Emini Veseli, B., **Perrotta, P.**, Van Wielendaele, P., Lambeir, A. M., Abdali, A., Bellosta, S., Monaco, G., Bultynck, G., Martinet, W., and De Meyer, G. R. Y. (2020) Small molecule 3PO inhibits glycolysis but does not bind to 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-3 (PFKFB3). *FEBS Lett*
3. **Perrotta, P.**, Pintelon, I., de Vries, M. R., Quax, P. H. A., Timmermans, J. P., De Meyer, G. R. Y., and Martinet, W. (2020) Three-Dimensional Imaging of Intraplaque Neovascularization in a Mouse Model of Advanced Atherosclerosis. *J Vasc Res*, 1-7
4. De Dominicis, C., **Perrotta, P.**, Dall'Angelo, S., Wyffels, L., Staelens, S., De Meyer, G. R. Y., and Zanda, M. (2020) [(18)F]ZCDD083: A PFKFB3-Targeted PET Tracer for Atherosclerotic Plaque Imaging. *ACS Med Chem Lett* **11**, 933-939
5. **Perrotta, P.**, Van der Veken, B., Van Der Veken, P., Pintelon, I., Roosens, L., Adriaenssens, E., Timmerman, V., Guns, P. J., De Meyer, G. R. Y., and Martinet, W. (2020) Partial Inhibition of Glycolysis Reduces Atherogenesis Independent of Intraplaque Neovascularization in Mice. *Arterioscler Thromb Vasc Biol* **40**, 1168-1181
6. Zhou, H., Mehta, S., Srivastava, S. P., Grabinska, K., Zhang, X., Wong, C., Hedayat, A., **Perrotta, P.**, Fernandez-Hernando, C., Sessa, W. C., and Goodwin, J. E. (2020) Endothelial cell-glucocorticoid receptor interactions and regulation of Wnt signaling. *JCI Insight* **5**
7. **Perrotta, P**., Emini Veseli, B., Van der Veken, B., Roth, L., Martinet, W., and De Meyer, G. R. Y. (2019) Pharmacological strategies to inhibit intra-plaque angiogenesis in atherosclerosis. *Vascul Pharmacol* **112**, 72-78
8. Emini Veseli, B., **Perrotta, P.**, De Meyer, G. R. A., Roth, L., Van der Donckt, C., Martinet, W., and De Meyer, G. R. Y. (2017) Animal models of atherosclerosis. *Eur J Pharmacol* **816**, 3-13

9. Ulrich, V., Rotllan, N., Araldi, E., Luciano, A., Skroblin, P., Abonnenc, M., **Perrotta, P.**, Yin, X., Bauer, A., Leslie, K. L., Zhang, P., Aryal, B., Montgomery, R. L., Thum, T., Martin, K., Suarez, Y., Mayr, M., Fernandez-Hernando, C., and Sessa, W. C. (2016) Chronic miR-29 antagonism promotes favorable plaque remodeling in atherosclerotic mice. *EMBO Mol Med* **8**, 643-653
10. Landskroner-Eiger, S., Qiu, C., **Perrotta, P.**, Siragusa, M., Lee, M. Y., Ulrich, V., Luciano, A. K., Zhuang, Z. W., Corti, F., Simons, M., Montgomery, R. L., Wu, D., Yu, J., and Sessa, W. C. (2015) Endothelial miR-17 approximately 92 cluster negatively regulates arteriogenesis via miRNA-19 repression of WNT signaling. *Proc Natl Acad Sci U S A* **112**, 12812-12817